Gradual Reactivation of Vascular Angiotensin I to Angiotensin II Conversion During Chronic ACE Inhibitor Therapy in Patients with Diabetes Mellitus

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2007 Aug 7

PMID 17676311

Citations 3

Authors

D C Sharman

A D Morris

A D Struthers

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: In chronic heart failure there is gradual reactivation of vascular tissue angiotensin I (AI) to angiotensin II (AII) conversion over time in patients taking chronic ACE inhibitor therapy. However, it remains unknown whether the same overall phenomenon occurs in other patients taking chronic ACE inhibitor therapy, such as patients with type 2 diabetes mellitus.

Methods: We studied 30 patients with type 2 diabetes mellitus (mean age 43.5 +/- 10.8 years), all of whom received lisinopril (20 mg/day) as part of their normal treatment. Over the course of the 18 month study, we made measurements at 0, 9 and 18 months. These measurements included plasma values for components of the renin-angiotensin-aldosterone system. In addition, we infused AI and AII into the brachial arteries of patients to assess vascular tissue AI to AII conversion.

Results: There were no significant changes in plasma renin activity, ACE, AI, AII or aldosterone during the study. In contrast, vascular AI to AII conversion was significantly (p = 0.01) greater at 18 months than at 0 months. There was no change over time in the response to infused AII.

Conclusions/interpretation: We have shown in vivo that vascular tissue AI to AII conversion gradually increases over time in patients with type 2 diabetes being treated with lisinopril. Further studies are required to determine whether this reactivation detracts from the cardioprotective effects of chronic ACE inhibitor therapy in diabetic patients, and if so, how best to overcome it.

Citing Articles

Pharmacodynamic Impact of Carboxylesterase 1 Gene Variants in Patients with Congestive Heart Failure Treated with Angiotensin-Converting Enzyme Inhibitors.

Nelveg-Kristensen K, Bie P, Ferrero L, Bjerre D, Bruun N, Egfjord M PLoS One. 2016; 11(9):e0163341.

PMID: 27662362 PMC: 5035013. DOI: 10.1371/journal.pone.0163341.

Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney.

Grobe N, Elased K, Cool D, Morris M Am J Physiol Endocrinol Metab. 2012; 302(8):E1016-24.

PMID: 22318946 PMC: 3330725. DOI: 10.1152/ajpendo.00515.2011.

Liver disease and the renin-angiotensin system: recent discoveries and clinical implications.

Lubel J, Herath C, Burrell L, Angus P J Gastroenterol Hepatol. 2008; 23(9):1327-38.

PMID: 18557800 PMC: 7166336. DOI: 10.1111/j.1440-1746.2008.05461.x.

References

. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355(9200):253-9. View

Massie B, Kramer B, Topic N . Lack of relationship between the short-term hemodynamic effects of captopril and subsequent clinical responses. Circulation. 1984; 69(6):1135-41. DOI: 10.1161/01.cir.69.6.1135. View

Lindholm L, Ibsen H, Dahlof B, Devereux R, Beevers G, de Faire U . Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):1004-10. DOI: 10.1016/S0140-6736(02)08090-X. View

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):145-53. DOI: 10.1056/NEJM200001203420301. View

Pfeffer M, McMurray J, Velazquez E, Rouleau J, Kober L, Maggioni A . Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349(20):1893-906. DOI: 10.1056/NEJMoa032292. View

Benjamin N, Cockcroft J, Collier J, Dollery C, Ritter J, Webb D . Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol. 1989; 412:543-55. PMC: 1190590. DOI: 10.1113/jphysiol.1989.sp017630. View

Mogensen C, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts R . Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000; 321(7274):1440-4. PMC: 27545. DOI: 10.1136/bmj.321.7274.1440. View

MacFadyen R, Lee A, Morton J, Pringle S, Struthers A . How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?. Heart. 1999; 82(1):57-61. PMC: 1729098. DOI: 10.1136/hrt.82.1.57. View

Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T . Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003; 361(9352):117-24. DOI: 10.1016/S0140-6736(03)12229-5. View

10.

Petrie M, PADMANABHAN N, McDonald J, Hillier C, Connell J, McMurray J . Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol. 2001; 37(4):1056-61. DOI: 10.1016/s0735-1097(01)01111-1. View

11.

Fukuhara M, Geary R, Diz D, Gallagher P, Wilson J, Glazier S . Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension. 2000; 35(1 Pt 2):353-9. DOI: 10.1161/01.hyp.35.1.353. View

12.

Hoshida S, Kato J, Nishino M, Egami Y, Takeda T, Kawabata M . Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation. 2001; 103(5):630-3. DOI: 10.1161/01.cir.103.5.630. View

13.

Ferrario C, Trask A, Jessup J . Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol. 2005; 289(6):H2281-90. PMC: 7203566. DOI: 10.1152/ajpheart.00618.2005. View

14.

McMurray J, Ostergren J, Swedberg K, Granger C, Held P, Michelson E . Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003; 362(9386):767-71. DOI: 10.1016/S0140-6736(03)14283-3. View

15.

Fyhrquist F, Hortling L, Gronhagen-Riska C . Induction of angiotensin I-converting enzyme by captopril in cultured human endothelial cells. J Clin Endocrinol Metab. 1982; 55(4):783-6. DOI: 10.1210/jcem-55-4-783. View

16.

Hirsch A, Talsness C, Schunkert H, Paul M, Dzau V . Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 1991; 69(2):475-82. DOI: 10.1161/01.res.69.2.475. View

17.

Jorde U, Ennezat P, Lisker J, Suryadevara V, Infeld J, Cukon S . Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation. 2000; 101(8):844-6. DOI: 10.1161/01.cir.101.8.844. View

18.

Farquharson C, Struthers A . Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol. 2002; 39(5):767-75. DOI: 10.1016/s0735-1097(02)01689-3. View

19.

Okamura T, Miyazaki M, Inagami T, Toda N . Vascular renin-angiotensin system in two-kidney, one clip hypertensive rats. Hypertension. 1986; 8(7):560-5. DOI: 10.1161/01.hyp.8.7.560. View

20.

Rakugi H, Kim D, Krieger J, Wang D, Dzau V, PRATT R . Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. J Clin Invest. 1994; 93(1):339-46. PMC: 293775. DOI: 10.1172/JCI116965. View